ISDA

Entry Detail

PDB ID:

3RX4

Keywords:

OXIDOREDUCTASE

Title:

Crystal Structure of Human Aldose Reductase complexed with Sulindac Sulfide

Biological Source:

Source Organism:

Homo sapiens

Host Organism:

Escherichia coli

PDB Version:

Deposition Date:

2011-05-10

Release Date:

2011-11-30

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.00 Å

R-Value Free:

0.20

R-Value Work:

0.15

R-Value Observed:

0.15

Space Group:

P 1 21 1

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Description:Aldose reductase
Chain IDs:A
Chain Length:336
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:P15121 Pfam ID:PF00248 EC:1.1.1.188

Ligand Molecules

NAP

SFI

Primary Citation

The molecular basis for inhibition of sulindac and its metabolites towards human aldose reductase.

Zheng, X, Zhang, L, Zhai, J, Chen, Y, Luo, H, Hu, X.Show

Febs Lett. 586 55 59 (2012)

PMID: 22155003 DOI: 10.1016/j.febslet.2011.11.023

Abstact

Sulindac (SLD) exhibits both the highest inhibitory activity towards human aldose reductase (AR) among popular non-steroidal anti-inflammatory drugs and clear beneficial clinical effects on Type 2 diabetes. However, the molecular basis for these properties is unclear. Here, we report that SLD and its pharmacologically active/inactive metabolites, SLD sulfide and SLD sulfone, are equally effective as un-competitive inhibitors of AR in vitro. Crystallographic analysis reveals that π-π stacking favored by the distinct scaffold of SLDs is pivotal to their high AR inhibitory activities. These results also suggest that SLD sulfone could be a potent lead compound for AR inhibition in vivo.

Legend

Protein

Chemical

Disease

Primary Citation of related structures